| Drug Name | (Xeljanz®( TOFACITINIB |
|---|---|
| Drug Class |
Immunosuppressant
|
| Risk minimization type |
Patient Card
|
| Specialty (Theraputic area) |
Rheumatology
|
| Risk |
Safety information about monitoring and Increased risk of pulmonary embolism and overall mortality with higher dose of XELJANZ (tofacitinib) for rheumatoid arthritis |
| Patient card |
|
| Health care provider guide |
|
| Dear Healthcare provider letter DHPC |
|
| Healthcare provider checklist |
|